Molecular Oncology 

In the Molecular Oncology pillar, we use large genomic and transcriptomic databases to identify clinically applicable therapeutic options for patients with solid tumours who either currently have no suitable drug therapy or have developed resistance to available treatments. Our main goal of the Molecular Oncology Pillar is to elucidate the molecular processes involved in the development of tumour recurrence and drug resistance, and thus develop more effective diagnostic and therapeutic procedures. This will require a deeper understanding of the mechanisms that enable resistance to develop, the identification of new drug targets and the identification of associated resistance biomarkers. The project will identify genetic variations affecting relevant molecular targets in a given patient by analysing large genomic and transcriptomic databases. By designing appropriate inhibitors, we will be able to provide personalized treatment to these patients, independent of histological type. Our aim is to demonstrate the feasibility of selection, experimentally validate the molecular correlations, prepare inhibitors and demonstrate their suitability as drugs, and develop a stratification protocol.